Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trials

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016
Volume 11
Issue 3

Cirrus Pharmaceuticals will launch services for manufacturing cGMP materials for early-phase clinical trials at its Raleigh-Durham, NC facility.

Cirrus Pharmaceuticals, a Kemwell Company, has announced that it is ready to launch services for manufacturing cGMP materials for early-phase clinical trials in a new suite at its Raleigh-Durham, NC site.

The company offers development and manufacturing capabilities for niche dosage forms. The company will manufacture metered dose inhalers (MDI) on its Pamasol pressure filling line in batch sizes up to 25L. One- and two-step filling as well as cold filling for suspension and solution MDIs will be offered.

Other services include dry powder filling in capsules for dry powder inhalers, and manufacture of nasal solutions, suspensions, and powders. Clinical manufacturing of other dosage forms that will be offered from the site are topicals, oral solids, and oral liquids.

Source: Cirrus Pharmaceuticals, a Kemwell Company

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content